InvestorsHub Logo
Followers 1511
Posts 35243
Boards Moderated 7
Alias Born 07/12/2004

Re: SC777 post# 5326

Friday, 12/14/2018 12:23:00 PM

Friday, December 14, 2018 12:23:00 PM

Post# of 5875
Thanks, good to know. I own shares because of the zero debt and $3.5 million in cash, plus their intellectual property and research portfolio.

A public acquirer could easily benefit from ImmunoCellular Therapeutics prior reporting compliance, ie., all Financials and Filings were current up to the date the company deregistered, and a private acquirer could file a FORM 10 to register their amalgamated companies with the SEC, benefitting from ImmunoCellular Therapeutics SEC compliance before the company deregistered.

Very low risk with this stock, as I see it.

All Financials and Filings up to Nov. 6,2018:

https://www.sec.gov/cgi-bin/browse-edgar?company=ImmunoCellular+Therapeutics&owner=exclude&action=getcompany

To bite the worm of incite is to bite the HOOK of the antagonist . They win .